The introduction of clotting factor concentrates in 1970 has improved the treatment of coagulopathic patients. Early and self-administration of these concentrates has resulted in a longer life span and a better life quality due to the rapid resolution of bleeding episodes. However, a rise in acute hepatitis was observed following the use of clotting factor concentrates. Before the introduction of virucidal procedures in the processing of factor concentrates, over 50% of hemophilic patients showed previous infections due to hepatitis B (HBV) and non A-non B viruses. This prevalence was higher than that observed in the normal population. A significant proportion of coagulopathic patients with chronic aggressive hepatitis showed cirrhotic evolution. The onset of clinical cirrhosis is estimated at between 12-18 years from the start of using clotting factor concentrates. In a recent study, liver failure occurred more frequently in HCV-positive hemophiliacs who were coinfected with HIV; moreover, HCV-RNA levels were significantly higher in HIV seropositive than in HIV seronegative hemophiliacs. In yet another experience, a high risk of developing hepatocellular carcinoma in HCV-positive hemophilic patients, especially those with concomitant HIV infection, was suggested. Recently, Lee outlined that the progression of hepatitis C to
severe liver failure in coagulopathic patients with HIV coinfection will put a considerable drain on resources in the coming years.

We report the case of a young HCV- and HIV seropositive hemophilic patient who presented rapid liver failure accelerated by severe deterioration of the immune system.

Case Report

The patient was first observed in 1974. He was eight years old and presented a history of recurrent hematomas and hemarthroses. He was diagnosed as suffering from severe hemophilia A (factor VIII:C < 1 U/dL). In 1975 the patient began receiving factor VIII:C concentrates. In 1984 and during subsequent follow-up we observed altered alanine aminotransferase (ALT) levels. In 1985 the patient was found to be seropositive for HIV infection, which was later confirmed by the Western blot method. The patient also showed seropositivity for HCV infection (1991) with the ELISA test, and this was confirmed by the RIBA method. HBsAg was negative. Up to 1991 (Table 1) ultrasound scans showed only a slight increase in the longitudinal diameter of the liver and a normal splenic longitudinal diameter without parenchymal alterations. In 1992 treatment with didanosine was started (400 mg/day) for a CD4+ lymphocyte count below 500 µL (Table 1). After six months the antiretroviral therapy was interrupted because of severe gastralgia. A marked decrease in the CD4+ lymphocyte count without HIV-related symptoms followed (Table 1). A progressive rise in polyclonal γ-globulin levels was observed IgG = 5,070 mg/dL - normal range 800-1,700 mg/dL; IgA = 2,380 mg/dL - normal range 100-470 mg/dL). Moreover, at this time the low levels of the C3 (17.9 mg/dL - normal range 50-90 mg/dL) and C4 (< 11 mg/dL - normal range 11-40 mg/dL) complement fractions were associated with abnormal levels of γ-glutamyl transeptidase (125 IU/L), alkaline phosphatase (447 IU/L), total bilirubin (3.9 mg/dL) and ammonemia (125 µmol/L). A drop in platelet count and an ultrasound-documented increase in the longitudinal hepatic and splenic diameters with inhomogeneity of the liver parenchyma and enlargement of the portal vein (13 mm) were progressively observed (Table 1). Duplex doppler hemodynamic studies with an electrically focused 3.75 MHz sectorial probe (Toshiba SSH 140-A) demonstrated a reduction of the mean flow velocity in the portal vein (10 cm/sec. - normal range 19±2 cm/sec.) and a flat spectrum of the flow in the suprahepatic veins. Esophagogram and esophagogastroscopy evidenced varicosities in the lower esophageal section (stage F1 by esophagogastroscopy).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4+ lymphocytes (N/µL)</td>
<td>700</td>
<td>680</td>
<td>510</td>
<td>410</td>
<td>150</td>
<td>51</td>
</tr>
<tr>
<td>Platelet count* (N.×10^9/L)</td>
<td>210±30</td>
<td>200±39</td>
<td>199±45</td>
<td>123±39</td>
<td>71±9</td>
<td>49±17</td>
</tr>
<tr>
<td>Total proteins (g/dL)</td>
<td>7.5</td>
<td>8.1</td>
<td>8.2</td>
<td>8.4</td>
<td>8.3</td>
<td>9.2</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>4.5</td>
<td>4.2</td>
<td>4.1</td>
<td>2.9</td>
<td>2.4</td>
<td>1.9</td>
</tr>
<tr>
<td>γ-globulins (%)</td>
<td>20</td>
<td>26</td>
<td>27</td>
<td>32</td>
<td>55</td>
<td>70</td>
</tr>
<tr>
<td>Longitudinal liver diameter (mm) (&lt; 120)</td>
<td>127</td>
<td>129</td>
<td>130</td>
<td>141</td>
<td>145</td>
<td>154</td>
</tr>
<tr>
<td>Longitudinal spleen diameter (mm) (&lt; 115)</td>
<td>112</td>
<td>112</td>
<td>115</td>
<td>122</td>
<td>135</td>
<td>155</td>
</tr>
</tbody>
</table>

* ± = standard deviation is reported.

Table 1. Outcome of immunological, hematological, biochemical and morphological parameters evaluated in the patient studied.
Chronic C hepatitis in HIV seropositive hemophilic patient

In 1994, albumin levels of less than 2 g/dL and evidence of edema in the lower limbs required substitutive treatment. In March 1995, sudden septic shock occurred that resulted in death within a few hours despite large spectrum antibiotic treatment. Many hemocultures performed at the time of admission had been positive for *Pseudomonas aeruginosa*. The patient was 29-year-old.

Statistical evaluation through linear regression showed a significant inverse correlation between the increase in the longitudinal diameter of the liver and the decrease in albumin levels (R-squared 0.98, p = 0.0001) and between the increase in the longitudinal diameter of the liver and the decrease in platelet count (R-squared 0.97, p = 0.0004) (Figure 1).

**Discussion**

Before virucidal methods were introduced in the processing of plasma derived clotting factor concentrates, infections due to transfusion-transmitted viruses were frequent among hemophiliacs and more than 90% of post-transfusion hepatites were caused by HCV virus. Among our population of 64 coagulopathic HIV-positive patients treated before 1985 with non-inactivated plasma derived concentrates, we found a prevalence of 85.9% HCV seropositive patients.

Recent studies have hypothesized a higher risk of rapid progression to cirrhosis and liver failure for patients with chronic C virus hepatitis who are coinfected with HIV. The outcome of our patient was characterized by slight liver involvement and a normal ultrasonographic scan as long as the CD4+ lymphocyte count remained above 500 per µL.

Biochemical parameters and hepatic ultrasonographic morphology rapidly worsened when the CD4+ lymphocyte count dropped below this level (Table 1).

The outcome of our case seems to indicate that liver failure was accelerated by the CD4+ lymphocyte count falling to lower than 200/µL, which is an independent parameter associated with progression to AIDS.

It is interesting to note that a significant correlation between the CD4+ lymphocyte count and the grade of cirrhosis is also reported in HIV seronegative patients with chronic C hepatitis. Moreover, *Pseudomonas aeruginosa* and other Gram-negative infections are a frequent deadly complication in the natural history of cirrhotic patients.

Our case confirms that the hypothesis of rapid liver failure in HCV positive hemophiliacs coinfected with HIV is accelerated by severe immunodeficiency and poorly related to antiretroviral treatment.
References